Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hyperlipoproteinemias

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 30 articles:
HTML format
Text format



Single Articles


    February 2017
  1. KHERA AV, Kathiresan S
    Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2017;376:498-9.
    PubMed     Text format    


  2. MARTIN AC, Watts GF
    Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2017;376:498.
    PubMed     Text format    


  3. KULLO IJ, Safarova MS
    Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2017;376:498.
    PubMed     Text format    


  4. HINGORANI AD, Futema M, Humphries S
    Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2017;376:499.
    PubMed     Text format    



  5. Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2017;376:498-500.
    PubMed     Text format    


    January 2017
  6. SCHULMAN AR, Vaidya A, Tavakkoli A, Jajoo K, et al
    Making the Connection.
    N Engl J Med. 2017;376:e5.
    PubMed     Text format    


    October 2016
  7. MCCRINDLE BW, Gidding SS
    What Should Be the Screening Strategy for Familial Hypercholesterolemia?
    N Engl J Med. 2016;375:1685-1686.
    PubMed     Text format    


  8. WALD DS, Bestwick JP, Morris JK, Whyte K, et al
    Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2016;375:1628-1637.
    PubMed     Text format     Abstract available


    September 2016
  9. LAMPSON BL, Gray SW, Cibas ES, Levy BD, et al
    CLINICAL PROBLEM-SOLVING. Tip of the Tongue.
    N Engl J Med. 2016;375:880-6.
    PubMed     Text format    


    May 2016
  10. CUSHMAN WC, Goff DC Jr
    More HOPE for Prevention with Statins.
    N Engl J Med. 2016;374:2085-7.
    PubMed     Text format    


    April 2016
  11. YUSUF S, Bosch J, Dagenais G, Zhu J, et al
    Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
    N Engl J Med. 2016.
    PubMed     Text format     Abstract available


    October 2015
  12. EVERETT BM, Smith RJ, Hiatt WR
    Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.
    N Engl J Med. 2015;373:1588-91.
    PubMed     Text format    


  13. SCHULMAN KA, Balu S, Reed SD
    Specialty Pharmaceuticals for Hyperlipidemia - Impact on Insurance Premiums.
    N Engl J Med. 2015.
    PubMed     Text format     Abstract available


    August 2015
  14. SABATINE MS, Wasserman SM, Stein EA
    PCSK9 Inhibitors and Cardiovascular Events.
    N Engl J Med. 2015;373:774-5.
    PubMed     Text format    


  15. GOEMANN IM, Londero TM, Dora JM
    PCSK9 Inhibitors and Cardiovascular Events.
    N Engl J Med. 2015;373:773-4.
    PubMed     Text format    


  16. AUER J, Berent R, Primus C
    PCSK9 Inhibitors and Cardiovascular Events.
    N Engl J Med. 2015;373:773.
    PubMed     Text format    


  17. ROBINSON JG, Kastelein JJ
    PCSK9 Inhibitors and Cardiovascular Events.
    N Engl J Med. 2015;373:774.
    PubMed     Text format    


    July 2015
  18. GAUDET D, Alexander VJ, Baker BF, Brisson D, et al
    Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
    N Engl J Med. 2015;373:438-47.
    PubMed     Text format     Abstract available


    April 2015
  19. STONE NJ, Lloyd-Jones DM
    Lowering LDL cholesterol is good, but how and in whom?
    N Engl J Med. 2015;372:1564-5.
    PubMed     Text format    


  20. NELSON CP, Hamby SE, Saleheen D, Hopewell JC, et al
    Genetically Determined Height and Coronary Artery Disease.
    N Engl J Med. 2015.
    PubMed     Text format     Abstract available


    March 2015
  21. SABATINE MS, Giugliano RP, Wiviott SD, Raal FJ, et al
    Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events.
    N Engl J Med. 2015.
    PubMed     Text format     Abstract available


  22. ROBINSON JG, Farnier M, Krempf M, Bergeron J, et al
    Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events.
    N Engl J Med. 2015.
    PubMed     Text format     Abstract available


    December 2014
  23. GAUDET D, Brisson D, Tremblay K, Alexander VJ, et al
    Targeting APOC3 in the familial chylomicronemia syndrome.
    N Engl J Med. 2014;371:2200-6.
    PubMed     Text format     Abstract available


    November 2014
  24. MAYER L
    Niacin for reduction of cardiovascular risk.
    N Engl J Med. 2014;371:1943.
    PubMed     Text format    


  25. SANTOS-GALLEGO CG, Badimon J
    Niacin for reduction of cardiovascular risk.
    N Engl J Med. 2014;371:1943.
    PubMed     Text format    


  26. VAN DEN OEVER IA, Nurmohamed MT, Lems WF
    Niacin for reduction of cardiovascular risk.
    N Engl J Med. 2014;371:1942.
    PubMed     Text format    


  27. HU M, Tomlinson B
    Niacin for reduction of cardiovascular risk.
    N Engl J Med. 2014;371:1941-2.
    PubMed     Text format    


  28. MENESES F
    Niacin for reduction of cardiovascular risk.
    N Engl J Med. 2014;371:1941.
    PubMed     Text format    


  29. REMBOLD CM
    Niacin for reduction of cardiovascular risk.
    N Engl J Med. 2014;371:1940-1.
    PubMed     Text format    


  30. LANDRAY MJ, Haynes R, Armitage J
    Niacin for reduction of cardiovascular risk.
    N Engl J Med. 2014;371:1943-4.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Hyperlipoproteinemias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: